

REFERENCIAS BIBLIOGRÁFICAS

1. Turck D., Braegger CP., Colombo C. et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. *Clinical Nutrition* 35 (2016) 557e577.
2. Lahiri T.,Hempstead SE., Brady C. et al Clinical Practice Guidelines from the Cystic Fibrosis Foundation for Pre-schoolers with Cystic Fibrosis.. *Pediatrics*. 2016;37 (4). pii: e20151784. doi: 10.1542/peds.2015-1784. Epub 2016 Mar 23.
3. Somaraju UR., Solis-Moya A .Pancreatic enzyme replacement therapy for people with cystic fibrosis. *Cochrane Database Syst Rev*. 2016 Nov 23;11.
4. Borowitz D., Robinson KA.,Rosenfeld M.,et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. *J Pediatr*. 2009;155(6 Suppl):S73-93
5. Castellani C., Duff A., Bell S. ECFS Best practice guidelines : the 2018 revision. *J cyst Fib* 20187:153-178
6. Tabori H., Arnold C.,Jaudszius A., et al. Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings.. *PloS One* 2017 May 4;12
7. Assis DN,. Freedman SD.Gastrointestinal Disorders in Cystic Fibrosis *Clin Chest Med* 2016; 37 :109–118
8. Debray D., Kelly D., Houwen R., el al. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease.. *J Cyst Fibros* 2011;(10)Suppl 2 S29-S36
9. Kobelska-Dubiel N, Klineciewicz B, Cichy W. Liver disease en cystic fibrosis. *Prz Gastroenterol*. 2014;9(3):136-41
10. Debray D., Narkewicz MR., Bodewes FAJA., et al. Cystic Fibrosis related Liver Disease: Research Challenges and Future Perspectives. *J Pediatr Gastroenterol Nutr*. 2017 Oct;65(4):443-448
11. Colombo C,Ellemunter H,.Houwen R.,et al. Guidelines for the diagnosis and management of DIOS in CF patients. . *J Cyst Fibros* 2011(10) Suppl 2;S24-S28
12. ESPGHAN Cystic Fibrosis Working Group. Definig DIOS and Constipation in Cystic Fibrosis With a Multicentre Study on the Incidence, Characteristics and Treatment of DIOS. *J Pediatric Gastroenterology and Nutrition* 2010; 50 : 38-442
13. Robinson N., DiMango E .Prevalence of Gastroesophageal Reflux in Cystic Fibrosis and Implications for Lung Disease. *Ann Am Thorac Soc*. 2014 Jul;11(6):964-8.

14. Maisonneuve P, Fitz Simmons SC, Neglia JP, Campbell PW 3rd, . Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. J Natl Cancer Inst. 2003 Mar 5;95(5):381-7
15. Hadjiliadis D., et al Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations. Gastroenterology 2017; 1-10
16. Maisonneuve P., Marshak BC., Knapp EA. Cancer risk in cystic fibrosis .J Natl Cancer Inst 2013 ; 105: 122-9.
17. Codner E., Acerini CL., Craig ME., et als. ISPAD Clinical Practice Consensus Guidelines 2018: What is new in diabetes care?., Pediatric Diabetes 2018; S 27:5
18. Moran A., Pillay K., Becker D.,et al .ISPAD Clinical Practice Consensus Guidelines 2018: Management of cystic fibrosis-related diabetes in children and adolescents. Pediatric Diabetes 2018 S27;64
19. Mayer-Davis EJ, Kahkoska AR, Jefferies C.,et al -ISPAD Clinical Practice Consensus Guidelines 2018: Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatric Diabetes 2018 27;7:19
20. Antoinette Morana, Kubendran Pillayb . ISPAD Clinical Practice Consensus Guidelines 2014 Compendium Management of cystic fibrosis-related diabetes in children and adolescents., Pediatric Diabetes 2014: 15(Suppl. 20): 65–76
21. Sermet-Gaudelius I., Bianchi ML., Garabedian M., et al .European cystic fibrosis bone mineralisation Guidelines. J Cyst Fibros 2011 ;10: S16-S 26